The Newsroom
Kraig Labs Opens the Global Market for Its Spider Silk with Historic Multi-Kilogram Order
First commercial spider silk yarn shipment for a global performance sports brand marks a milestone alongside record production and Project Atlas advances Houston, Texas (www.wallsreet-pr.com)—
NTHI Gains Roth Capital Buy Rating Ahead of Anticipated October FDA Meeting
Roth sees potential fourth-quarter pivotal trial starts, adding upcoming milestones to NeOnc’s expanding analyst coverage September 24, 2026 www.wallsreet-pr.com New analyst coverage is putting NeOnc
Get In, I’m Buying!
Investor Determination to Beat Cancer: NeOnc’s Institutional Backing, Executive Commitment and Latest Capital Move Tell a Consistent Story HOUSTON, Sept. 17, 2026 www.wallstreet-pr.com NeOnc Technologies
NeOnc’s NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival reaching approximately 26 months Houston, Texas (www.wallstreet-pr.com) –
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
Houston, Texas (www.wallstreet-pr.com) — NeOnc Technologies Holdings (Nasdaq: NTHI) is set up for a potential high impact catalyst day with what market observers are describing
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc’s Global Neuro-Oncology Strategy
International Regulatory Validation Has Preceded Several Recent FDA Success Stories, Though Significant Development Risks Remain Houston, Texas (www.wallstreet-pr.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) recently achieved